Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability [Yahoo! Finance]
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: Yahoo! Finance
TheFly reported on April 7 that Jefferies lowered its price target on ABUS from $7.00 to $5.50 while maintaining a Buy rating. The revision was driven by updated expectations around the outcome of Moderna's appeal in ongoing litigation, which could influence a potential $1.3 billion payment tied to the case. The firm adjusted its probability assessment, increasing the likelihood of a Moderna win on appeal, which in turn reduced its valuation outlook for ABUS. On March 23, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported its fourth-quarter and full-year 2025 financial results and provided a corporate update. The company highlighted its ongoing litigation-related developments, including a settlement agreement with Moderna and Genevant under which ABUS is entitled to a portion of a $950 million upfront payment expected in July 2026, along with potential eligibility for an additional $1.3 billion contingent on an appellate outcome. Jefferies Sees Reduced Upside for Arbutus Biopha
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis BGlobeNewswire
- Arbutus Biopharma GAAP EPS of -$0.17 misses by $0.13, revenue of $14.08M beats by $13.47M [Seeking Alpha]Seeking Alpha
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook [Yahoo! Finance]Yahoo! Finance
ABUS
Earnings
- 8/6/25 - Beat
ABUS
Sec Filings
- 4/15/26 - Form 8-K
- 4/14/26 - Form DEFA14A
- 4/14/26 - Form DEF
- ABUS's page on the SEC website